anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Solutions of the flavonoids in an organic solvent, which optionally contains water, are subjected to column chromatography. Used as sorbents are granular oxides, hydroxides or basic salts of doubly charged cations which are insoluble in the solvent used but are soluble in dilute acids and whose aqueous suspensions have a pH of 7 - 13. It is possible to use a single column or a plurality of columns which are arranged in series and which are packed with the same or with different sorbent(s). The concomitant substances are washed out by elution with organic solvents in which the sorbents are insoluble. The resulting flavonoid-sorbent complexes are dissolved in dilute acids, and the flavonoids are isolated from the resulting acid solution. The process makes it possible smoothly to remove the concomitant substances without losses of flavonoids and can be used on the industrial scale. Flavonoids are an important and widespread class of vegetable pigments and have a good effect on the heart and blood vessels.
The invention provides a novel human tumor necrosis factor-related apoptosis-inducing ligand receptor DR (death receptor) extracellular antibody. The death receptor agonistic polyvalent antibody can identify identical or similar epitopes of DR4 and DR5 to form the polyvalent antibody and induce the tumor cells expressing DR4 and/or DR5 to generate apoptosis. A tetravalent antibody is formed through connection of a human p53 structure domain. The tetravalent antibody comprises a heavy chain variable region and a light chain variable region. An amino acid sequence of the heavy chain variable region is shown as SEQIDNo.1; and an amino acid sequence of the heavy chain variable region is shown as SEQIDNo.2. The agonistic polyvalent antibody has obviously stronger capacity for simultaneously expressing tumor apoptosis of DR4 and DR5 than the agonistic antibody aiming at DR4 or DR5 only does. The invention also provides an application of the death receptor agonistic polyvalent antibody in preparing an anti-tumor drug.
Expression of cannabinoid receptors are examined in mucosal biopsies of the colon and blood leukocytes of patients with inflammatory bowel disease (IBD) or colon cancer in comparison to healthy individuals by polymerase chain reaction, Western Blots and flow cytometry. Colonic endoscopic biopsies and blood are collected from adult patients with confirmed active Ulcerative colitis (UC) and Crohn's disease (CD), adult UC and CD patients in remission, colon cancer patients and from healthy individuals (controls). Biopsies from healthy individuals (control group) will have undergone colonoscopy during standard screening for colorectal cancer or for the diagnostic workup of gastrointestinal symptoms without endoscopic or histologic evidence of colonic disease. For UC patients, duration and location of disease (Montreal classification), endoscopic (Mayo score) and clinical activity score, histological features and current and previous treatments (5-aminosalicylic acid, corticosteroids, immunomodulators) will be recorded. For CD patients, duration and location of disease is assessed, a HarveyBradshaw Index and activity will be scored, histological features and current and previous treatments will be recorded. Blood is collected and immediately processed for flow cytometric experiments. Phospholipids are measured in serum and in colonic mucosal biopsy samples of all cohorts by mass spectrometry.
A cleviprex fat emulsion concentrated solution, a preparation method and an application thereof belong to the field of pharmacology and pharmaceutics. According to the invention, the defect that a traditional fat emulsion preparation technology is complex and stability is poor is overcome. The preparation technology provided by the invention is simple; the general physical stirring process is only needed; and no homogenization technology is required. A product prepared in the invention can be sterilized through a 0.22-micron microfiltration membrane; in clinical use, the product can be spontaneously emulsified after diluted by the use of an aqueous solution such as normal saline or a glucose solution, etc. and slightly oscillated; and under optimized conditions, average particle size is about 0.2 micron, and injection fat emulsion characteristics are fully embodied. The product has good fluidity, will not be retained on the wall, is single-phase, transparent and clear in appearance, can undergo clarification detection and will not cause preparation stratification after multigelation. The product is used in blood pressure control during surgical operation and control of acute blood pressure elevation after operation, and also can be used in controlling blood pressure of hypertensives who are not suitable for oral administration or fail in oral administration.
Cryptococcal meningitis is an AIDS-defining illness mostly caused by the fungus, Cryptococcus neoformans. In high-income countries, the use of amphotericin B in combination with a more expensive drug, flucytosine, is most effective for the management of cryptococcal meningitis; but access to flucytosine is severely limited in middle and low-income countries. In Myanmar, currently recommended regimen for cryptococcal meningitis are combination of amphotericin B with fluconazole. Although amphotericin plus flucytosine followed by fluconazole therapy is the currently preferred regimen in WHO treatment guidelines, it is not still commonly used in Myanmar clinical practice because of its limited availability. Therefore, the data regarding tolerability and clinical effectiveness of flucytosine are unavailable for Myanmar patients.

Although trials were carried out for investigating the effectiveness of flucytosine in the HIV population of Africa, the variability in drug response can occur in Myanmar patients due to the racial and genetic differences and whether it is effective and safe for Myanmar people is a great curiosity question for clinicians and healthcare workers. In Myanmar, amphotericin plus flucytosine followed by fluconazole regimen will be supplied by National AIDS Program (NAP) and indicated in 2020. Thus, the documents for effectiveness and safety profile need to be established. This is the reason that the effectiveness and safety of amphotericin B with flucytosine and fluconazole combination therapy should be studied. From this study, it can provide information to physicians regarding the effectiveness as well as safety of those drugs in the management of cryptococcal meningitis in HIV patients.
The transition from elementary school to middle school presents a complex set of challenges for adolescents. These include increased expectations for time management and self-monitoring, renegotiation of rules and boundaries with parents, increased peer influence, and pubertal changes. For children in foster care, this transition is further complicated by issues such as a possible history of maltreatment, unpredictable changes in their living situations, and difficulty explaining their foster care background to peers and teachers. Such issues may be more serious for girls in foster care. Social problems for these girls in middle school can lead to a number of negative effects, including delinquency, substance abuse, poor school performance, mental health problems, and participation in risky sexual behavior. Despite such risks, adolescent girls are less likely to receive specialty mental health or school-based services than their male counterparts. This study is aimed at determining the effectiveness of a preventive intervention for preadolescent girls living in foster/kinship care. The intervention targets include preventing delinquency, initiation of substance use, participation in risky sexual behavior, school truancy and failure, and mental health problems.

Participants were randomly assigned to receive either the preventive intervention or usual foster care services in the summer before entering middle school (typically sixth grade). The preventive intervention consisted of weekly training and support sessions for both participants and their foster or kin parents. The sessions began at study start and continued throughout participants' first year in middle school. Participants' relationship development, delinquency, school behavior and performance, sexual behavior, and substance use were assessed through questionnaires. Parenting practices were assessed through interviews. Assessments were conducted at study entry and at Months 6, 12, and 24, and 36. A new, follow-up assessment on the girls' decision making was conducted at age 14-16.
<P>PROBLEM TO BE SOLVED: To enable the diagnostic reading of medical images smoothly by using an inexpensive portable terminal with a relatively low processing capacity.  <P>SOLUTION: An application server of a data center distributes images 36 for diagnostic reading received from a client to the portable terminal 22 of a physician involved to support for the diagnostic reading using the portable terminal 22. When distributing the entire photographing range of the images 36, the application server generates an overall image 53 by carrying out the processing of curtailing data volume of the data of the images 36 with an image processing part 41b. In the distribution confined to a part 36a of the photographing range, the data corresponding to the part 36a is cut out of the original data to generate a partial image 54. This eliminates the processing of curtailing data volume to make the resolving power of the partial image 54 higher than that of the overall image 53.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The treatment arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use. Additionally, they will be paid up to $1 per day for perfect medication adherence.
Described is a method of treating chronic compartment syndrome in a muscle of a mammal, particularly exertional compartment syndrome. The method includes introducing an effective amount of a nerve-blocking toxin, such as human botulinum toxin into the muscle. In addition to treating chronic or exertional compartment syndrome, a method is included and described of confirming diagnosis of exertional compartment syndrome in a muscle of a mammal. In the method, venous compression and/or expansion in a mammal in an area of a muscle having a symptom associated with exertional compartment syndrome is evaluated by comparing venous flow at rest and after stress on the muscle. An anaesthetic is used to block a nerve supplying motor function to the muscle causing compression of a blood vessel. The mammal is evaluated after the block of the nerve to determine if the symptom associated with exertional compartment syndrome is alleviated
The present invention discloses medicine for treating vitreous opacity and a preparation method thereof, which belongs to the technical field of manufacturing Chinese patent medicine. The present invention mainly solves the therapy problem of vitreous opacity caused by hemorrhage, inflammation and operations. The present invention comprises components of the following parts by weight: 10 to 20 of Danshen root, 10 to 20 of angelica, 10 to 20 of peach seeds, 10 to 20 of hemlock parsley, 25 to 30 of radix rehmanniae preparata, 8 to 15 of laminaria and 10 to 20 of liquoric root. In the preparation method, medicinal materials of which the impurities are removed are decocted in water, and decoction liquid is mixed and filtered; concentrated filter liquid is added with excipients to form Chinese patent medicine preparation. The medicine of the present invention belongs to a preparation type of dissolvable granules and can also be any other preparation types of pharmacy. Hygienics and pharmacology inspection shows that the medicine preparation has the advantages of stable quality, obvious therapeutic effect and no obvious side effect, and accords with pharmacopoeia standards; therefore, the present invention can be widely used for treating patients of vitreous opacity.
PROBLEM TO BE SOLVED: To provide a detergent which contributes to improve wrinkles, sag, and darkening in climacteric by incorporating polyoxyethylene methyl glucoside and polyoxyethylene polyoxyopropylene glycol into the same. SOLUTION: This detergent contains 0.01-20 wt.%, pref. 0.05-10 wt.%, still pref. 0.1-5 wt.%, polyoxyethylene methyl glucoside having a structure wherein the hydroxyl group at the 1-position of glucose has been etherified; and a polyoxyethylene group comprising 2-20, pref. 5-17, still pref. 7-15, oxyethylene units has been bonded to the hydroxyl group at the 6-position and 0.001-10 wt.%. pref. 0.005-5 wt.%, polyoxyethylene polyoxypropylene glycol having a structure wherein a polyoxypropylene group has been bonded through an ether linkage to one of two terminal hydroxyl groups of polyoxyethylene; the average number of oxyethylene units in the polyoxyethylene group is 100-2,000; and the average number of oxypropylene units in the polyoxypropylene group is 5-50.
OBJECTIVE: Hypoglycemia is a frequent occurrence in chronic kidney disease patients due to alterations in glucose and insulin metabolism. However, there are sparse data examining the predictors and clinical implications of hypoglycemia including mortality risk among incident hemodialysis patients.
DESIGN AND METHODS: Among 58,304 incident hemodialysis patients receiving care from a large national dialysis organization over 2007-2011, we examined clinical characteristics associated with risk of hypoglycemia, defined as a blood glucose concentration <70 mg/dL, in the first year of dialysis using expanded case-mix + laboratory logistic regression models. We then examined the association between hypoglycemia during the first year of dialysis with all-cause mortality using expanded case-mix + laboratory Cox models.
RESULTS: In the first year of dialysis, hypoglycemia was observed among 16.8% of diabetic and 6.9% of nondiabetic incident hemodialysis patients. In adjusted logistic regression models, clinical characteristics associated with hypoglycemia included younger age, female sex, African-American race, presence of a central venous catheter, lower residual renal function, and longer dialysis session length. In the overall cohort, patients who experienced hypoglycemia had a higher risk of all-cause mortality risk (reference: absence of hypoglycemia): adjusted hazard ratio (95% confidence interval) 1.08 (1.04, 1.13). In stratified analyses, hypoglycemia was also associated with higher mortality risk in the diabetic and nondiabetic subgroups: adjusted hazard ratios (95% confidence interval's) 1.08 (1.04-1.13), and 1.17 (0.94-1.45), respectively.
CONCLUSIONS: Hypoglycemia was a frequent occurrence among both diabetic and nondiabetic hemodialysis patients and was associated with a higher mortality risk. Further studies are needed to identify approaches that reduce hypoglycemia risk in the hemodialysis population.
Press a small dab (about 1/4 inch) to the lesion until a thin film develops. A larger quantity may be required for coverage of some lesions. For optimal results use only enough to coat the lesion with a thin film. Do not rub in. Attempting to spread this preparation may result in granular, gritty sensation and cause it to crumble. After application, however, a smooth, slippery film develops.

The preparation should be applied at bedtime to permit steroid contact with the lesion throughout the night. Depending on the severity of symptoms, it may be necessary to apply the preparation two or three times a day, preferably after meals. If significant repair or regeneration has not occurred in seven days, further investigation is advisable.
Procedure for the obtaining 2- (2 '' - benzofuranil) -4-bromometil-2-p-chlorofenil-1,3-dioxalane. Consists of the reaction of a formula (I) cetone with 1 to 3 times molar of epibromhydrine, in the presence of a lewis acid as a catalyst. The reaction starts in a chlorinated solvent at low temperature between 0 and 5c., and completes temperatures between the environment and the ebullition of the reactioning mixture. To the product obtained, a sodium or potassium hydroxide dissolution is added up to ph basic, decayed, washed, dry, separates the solvent and dissolves at reduced pressure. This compound has application for the obtaining of the amino dioxolanica ita 362, of pharmacological activity. (Machine-translation by Google Translate, not legally binding)
The patients assigned to this group did not receive any type of intervention during the 4 weeks. They were asked not to change their habits or receive any other type of treatment.
BACKGROUND: Stent dislodgement is a life-threatening complication that can result in coronary artery embolization, stent thrombosis, acute myocardial infarction, and even death. Severely angulated, heavily calcified, and previously stented coronary arteries are associated risk factors. With the development of different lesion preparation techniques and the drug eluting stent era, the reported incidence of stent dislodgement has decreased to < 1% in the last few years.
CASE PRESENTATION: We report a case of a 64-year-old Moroccan man complicated during percutaneous intervention in the left main artery by the loss of two stents. This complication was successfully managed by passing the stent's balloon into the stent and then fully expanding it. In our case, the device's characteristics were involved and could play a role in such complications, but it is still not well understood.
CONCLUSIONS: The main treatment option is stent retrieval with different available techniques. If retrieval of the stent is impossible, crushing it against the blood vessel wall could be considered.
The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.
The invention is related to multivalent immunogenic compositions comprising more than one <i>S. pneumoniae</i> polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an <i>S. pneumoniae</i> serotype conjugated to a carrier protein, wherein the serotypes of <i>S. pneumoniae</i> are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against <i>S. pneumoniae</i> infection and diseases caused by <i>S. pneumoniae</i>. The compositions of the invention are also useful as part of treatment regimens that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
Pseudomonas peritonitis is often severe and associated with less than 50% complete cure rate, often requiring catheter removal, and transfer to HD. International guidelines recommend that peritoneal catheter should be removed if peritoneal dialysis (PD) effluent does not clear after 5 days of appropriate antibiotic therapy defining the episode as refractory peritonitis. To avoid the shift to hemodialysis (HD), the simultaneous removal and replacement of the peritoneal catheter (SCR) has been employed to treat recurrent peritonitis or tunnel infections associated with peritonitis, obtaining satisfactory outcomes. However, the use of SCR is still controversial in refractory episodes. At present there is growing evidence that refractory peritonitis can be sustained by bacterial adherence along the intraperitoneal portion of the catheter, especially when Pseudomonas species are involved. We describe a case of refractory peritonitis sustained by P. aeruginosa that after a partial response to antibiotics has been successfully treated by SCR.
The use of sumatriptan succinate tablets is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of sumatriptan succinate tablets. Some of these reactions occurred in patients without known CAD. Sumatriptan succinate tablets may cause coronary artery vasospasm (Prinzmetal's angina), even in patients without a history of CAD.   
  
Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving sumatriptan succinate tablets. If there is evidence of CAD or coronary artery vasospasm, sumatriptan succinate tablets are contraindicated. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administering the first dose of sumatriptan succinate tablets in a medically supervised setting and performing an electrocardiogram (ECG) immediately following administration of sumatriptan succinate tablets. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of sumatriptan succinate tablets.
CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. It is planned that all patients will continue their double-blind treatment until the last patient is randomized in the study plus 18 months. The study is divided into 2 parts, the Primary Evaluation Treatment period part and the Open-Label Extension period of Study.
Considering the current prevalence in obesity and sarcopenia globally, this study aimed to summarize the development of sarcopenic obesity research to establish the topic's past, present, and future research direction using a bibliometric analysis. A comprehensive search for publications on sarcopenia and obesity was conducted in the Web of Science (WoS) database until the 31st of December 2023. We performed a detailed descriptive analysis, considering metrics like sources, authors, and documents, along with analyzing conceptual and social structures to map sarcopenic obesity research. Between 1993 and 2023, there were 4978 publications on sarcopenic obesity, representing 22.6% of the whole sarcopenia research (22070). Most published articles were originals (74.6%), and one of the highest increments in the fields was seen after 2010. The most significant contribution in this research area falls under the categories of Nutrition & Dietetics, Gerontology, and Geriatrics & Gerontology. Among regions, scientific production was located in 93 different countries. The United States, China, and South Korea had the highest contributions. The most relevant keywords were sarcopenia, obesity, and body composition. Research on sarcopenic obesity primarily focuses on epidemiology and identifying risk factors and outcome predictors. Yet, there is a shortage of research addressing prevention, early detection, and treatments to enhance the health of individuals with sarcopenia.
Experimental group 1: Breastfeeding training for successful breastfeeding in twin babies will be given to the online training group. The training will be carried out by the researchers (DM) and (SYC) using visual training tools (power point presentation, simultaneous breastfeeding animations in twin babies and breastfeeding guide). Due to the Covid-19 pandemic process, it will be carried out online and remotely. Training on successful breastfeeding in twin babies will be carried out in two sessions at a time. In the first session, about 45 minutes of online slide-assisted training on successful breastfeeding in twin babies and the importance of breast milk will be conducted and questions of pregnant women will be answered. Total training will take approximately one and a half hours.